NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free ETON Stock Alerts $3.12 -0.09 (-2.80%) (As of 01:07 PM ET) Add Compare Share Share Today's Range$3.12▼$3.2750-Day Range$3.06▼$4.5952-Week Range$2.42▼$5.81Volume10,194 shsAverage Volume66,427 shsMarket Capitalization$80.15 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Eton Pharmaceuticals alerts: Email Address Eton Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside214.5% Upside$10.00 Price TargetShort InterestHealthy0.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector527th out of 907 stocksPharmaceutical Preparations Industry242nd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEton Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.98% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eton Pharmaceuticals has recently decreased by 9.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETON. Previous Next N/A News and Social Media Coverage Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.16% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.86% of the stock of Eton Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -106.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -106.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.Go here now for this breaking story. About Eton Pharmaceuticals Stock (NASDAQ:ETON)Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Read More ETON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETON Stock News HeadlinesMarch 22, 2024 | markets.businessinsider.comEton Pharma Buys U.S. Rights To PKU GOLIKE From Relief TherapeuticsMarch 22, 2024 | finance.yahoo.comRelief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKEApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 22, 2024 | globenewswire.comEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaMarch 17, 2024 | theguardian.com‘I don’t think I developed emotionally’: Earl Spencer on the pain of boarding-school abuseMarch 17, 2024 | investing.comEarnings call: Eton Pharmaceuticals reports robust Q4 growthMarch 16, 2024 | finance.yahoo.comETON Apr 2024 5.000 callMarch 16, 2024 | seekingalpha.comEton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call TranscriptApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 16, 2024 | benzinga.comRecap: Eton Pharmaceuticals Q4 EarningsMarch 15, 2024 | finance.yahoo.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comQ4 2023 Eton Pharmaceuticals Inc Earnings CallMarch 14, 2024 | finance.yahoo.comEton Pharmaceuticals Inc (ETON) Reports Robust Sales Growth and Pipeline Progress in Q4 and ...March 14, 2024 | globenewswire.comEton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comEton Pharmaceuticals Earnings PreviewMarch 13, 2024 | msn.comEton Pharmaceuticals Q4 2023 Earnings PreviewMarch 13, 2024 | markets.businessinsider.comEton Pharmaceuticals earnings preview: what Wall Street is expectingMarch 13, 2024 | msn.comEarl Spencer’s horrific first experience of sex was all too typical for an upper-class maleMarch 12, 2024 | thetimes.co.ukCharles Spencer: ‘Boarding school killed a part of me’March 11, 2024 | washingtonpost.comPrincess Di’s brother, Charles Spencer, recounts childhood horrorsMarch 11, 2024 | msn.comCharles Spencer, Princess Diana’s brother, speaks out about ‘devastating’ abuse at British boarding schoolMarch 11, 2024 | thetimes.co.ukBoris Johnson’s secret flight to meet autocrat Maduro in VenezuelaMarch 11, 2024 | msn.comEarl Spencer reveals abuse at boarding schoolFebruary 29, 2024 | globenewswire.comEton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024February 22, 2024 | benzinga.comEton Pharmaceuticals Stock (NASDAQ:ETON) Dividends: History, Yield and DatesFebruary 21, 2024 | globenewswire.comEton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid FormulationJanuary 23, 2024 | finance.yahoo.comEton Pharmaceuticals (NASDAQ:ETON) investors are sitting on a loss of 50% if they invested three years agoSee More Headlines Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ETON CUSIPN/A CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+211.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E Ratio12.35 P/E GrowthN/ANet Income$-940,000.00 Net Margins-2.96% Pretax Margin-2.18% Return on Equity-6.21% Return on Assets-3.17% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.60 Sales & Book Value Annual Sales$31.64 million Price / Sales2.61 Cash Flow$0.00 per share Price / Cash Flow1,016.96 Book Value$0.60 per share Price / Book5.35Miscellaneous Outstanding Shares25,690,000Free Float22,307,000Market Cap$82.46 million OptionableOptionable Beta1.17 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Sean E. Brynjelsen (Age 52)President, CEO & Director Comp: $868.13kMr. James R. Gruber CPA (Age 52)CFO, Treasurer & Secretary Comp: $457.58kMr. David C. Krempa (Age 35)Chief Business Officer Ms. Ingrid HoosSenior Vice President of Regulatory AffairsMr. Kevin GuthrieExecutive VP of Commercial OperationsKey CompetitorsQ32 BioNASDAQ:QTTBReviva PharmaceuticalsNASDAQ:RVPHChimerixNASDAQ:CMRXLifeVantageNASDAQ:LFVNAssertioNASDAQ:ASRTView All CompetitorsInstitutional OwnershipWestside Investment Management Inc.Bought 10,850 shares on 4/19/2024Ownership: 2.234%Opaleye Management Inc.Bought 99,617 shares on 2/15/2024Ownership: 9.859%Essex Investment Management Co. LLCSold 31,403 shares on 2/8/2024Ownership: 0.306%Victory Capital Management Inc.Bought 27,979 shares on 2/5/2024Ownership: 0.109%Bailard Inc.Bought 22,639 shares on 2/2/2024Ownership: 0.088%View All Institutional Transactions ETON Stock Analysis - Frequently Asked Questions Should I buy or sell Eton Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ETON shares. View ETON analyst ratings or view top-rated stocks. What is Eton Pharmaceuticals' stock price target for 2024? 1 Wall Street analysts have issued 12 month price objectives for Eton Pharmaceuticals' shares. Their ETON share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 214.5% from the stock's current price. View analysts price targets for ETON or view top-rated stocks among Wall Street analysts. How have ETON shares performed in 2024? Eton Pharmaceuticals' stock was trading at $4.38 at the start of the year. Since then, ETON stock has decreased by 27.4% and is now trading at $3.18. View the best growth stocks for 2024 here. Are investors shorting Eton Pharmaceuticals? Eton Pharmaceuticals saw a drop in short interest in March. As of March 31st, there was short interest totaling 220,400 shares, a drop of 9.3% from the March 15th total of 242,900 shares. Based on an average trading volume of 70,600 shares, the days-to-cover ratio is currently 3.1 days. Currently, 1.0% of the company's stock are sold short. View Eton Pharmaceuticals' Short Interest. When is Eton Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ETON earnings forecast. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.05. The business had revenue of $7.31 million for the quarter, compared to analysts' expectations of $7.70 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 6.21% and a negative net margin of 2.96%. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA). When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Westside Investment Management Inc. (2.23%). Insiders that own company stock include Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ETON) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
